Cancer surgery avoidance study withdrawn before it began
NCT ID NCT06410534
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study aimed to see if the immunotherapy drugs nivolumab and ipilimumab could help people with colorectal or gastroesophageal cancer avoid or delay major surgery. It was designed for adults with stage I to III cancers. However, the trial was withdrawn by the sponsor before enrolling any participants, so no data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nivolumab and ipilimumab
- What this could lead to
- If this approach had worked, it could have pointed toward a way for some patients to avoid major surgery and preserve their organs.
- What could go wrong
- The study was withdrawn before any participants were enrolled, so no results are available. It is unknown whether the combination would have been effective or safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?